Skip to main content
Premium Trial:

Request an Annual Quote

Alercell to Distribute Amoy Diagnostic Ros1 Gene Fusion Detection Kit in US

NEW YORK – Alercell said Monday that it has begun distributing Amoy Diagnostics' ROS1 gene fusion detection kit under a master distribution agreement the two companies signed last month.

Amoy's kit is a real-time PCR assay for the qualitative detection of 14 ROS1 gene fusions in RNA extracted from formalin-fixed, paraffin-embedded tumor samples. These fusions define a unique molecular subset of non-small cell lung cancer.

Financial terms of the agreement were not disclosed, but Alercell said the tests are now available through its corporate office in Bozeman, Montana. They are initially for research-use only pending clearance by the US Food and Drug Administration.

Alercell has signed similar distribution deals in the past, including an agreement with Zeesan Biotech this April for that firm's leukemia fusions screening and genotyping kit.


The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.